Nasdaq · Healthcare
Surrozen, Inc./DE (SRZN)
As-reported financials and recent SEC filings for Surrozen, Inc./DE, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$3.5M
Net income
$-242.0M
Net margin
—
Diluted EPS
$-32.37
ROE
128.9%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.5M | $10.7M | $0 | $12.5M | $0 |
| Gross profit | — | — | — | — | — |
| Operating income | $-42.1M | $-25.5M | $-45.8M | $-44.3M | $-54.4M |
| Net income | $-242.0M | $-63.6M | $-43.0M | $-36.0M | $-54.6M |
| Diluted EPS | $-32.37 | $-7.22 | $-7.11 | $-5.19 | $-8.10 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-16
View on EDGAR →42026-06-16
View on EDGAR →42026-06-16
View on EDGAR →42026-06-16
View on EDGAR →42026-05-19
View on EDGAR →SCHEDULE 13D/A2026-05-18
View on EDGAR →SCHEDULE 13G/A2026-05-15
View on EDGAR →SCHEDULE 13G/A2026-05-15
View on EDGAR →Largest Healthcare peers
Go deeper on SRZN
Search Surrozen, Inc./DE’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.